


## CLAIMS:

1. A compound of formula (I),



(I)

5

or a pharmaceutically acceptable salt or solvate thereof, wherein

$R^1$  represents  $C_1$ - $C_6$  alkyl,  $-(CH_2)_c$ -[ $C_3$ - $C_8$  cycloalkyl]-,  $-(CH_2)_c$ -W or  $-(CH_2)_c$ -Z- $(CH_2)_d$ -W;

- 10 W represents  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkyloxy,  $-CO_2$ [ $C_1$ - $C_6$  alkyl],  $-CONR^4R^5$ , a phenyl group,  $NR^4R^5$ ,  $het^2$  or  $het^3$ , the phenyl group being optionally substituted with one or more groups independently selected from halogen,  $CF_3$ ,  $OCF_3$ ,  $R^3$ ,  $OR^3$ ,  $CO_2R^3$ ,  $CONR^4R^5$ , CN,  $SO_2NR^4R^5$  and  $NR^3SO_2Me$ ;

- 15 Z represents O or  $S(O)_g$ ;

g represents 0, 1 or 2;

- 20  $R^2$  represents a phenyl group, optionally fused to a 5- or 6- membered aryl or heterocyclic group which may contain one or more heteroatoms selected from N, O or S; the phenyl group and the optionally fused group being optionally substituted with one or more groups independently selected from the list defined below;

- 25 Ring A represents a 4-, 5- or 6- membered saturated heterocyclic group containing at least one N;

Ring B represents a phenyl group or  $het^1$ , each group being optionally substituted with one or more groups independently selected from the list defined below;

$R^7$  independently represents H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>3</sup>, -(CH<sub>2</sub>)<sub>e</sub>-R<sup>3</sup> or -(CH<sub>2</sub>)<sub>f</sub>-O-(CH<sub>2</sub>)<sub>e</sub>-R<sup>3</sup>;

at each occurrence R<sup>3</sup> independently represents H, C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by Y,  
5 -(CH<sub>2</sub>)<sub>g</sub>-[C<sub>3</sub>-C<sub>8</sub> cycloalkyl], phenyl, benzyl, pyridyl or pyrimidyl;

at each occurrence R<sup>4</sup> and R<sup>5</sup> independently represent H, C<sub>1</sub>-C<sub>6</sub> alkyl (optionally substituted with C<sub>1</sub>-C<sub>6</sub> alkyloxy), (CH<sub>2</sub>)<sub>g</sub>CO<sub>2</sub>-[C<sub>1</sub>-C<sub>6</sub> alkyl], -SO<sub>2</sub>Me, -(CH<sub>2</sub>)<sub>g</sub>-[C<sub>3</sub>-C<sub>8</sub> cycloalkyl], SO<sub>2</sub>Me, phenyl, benzyl, pyridyl or pyrimidyl; or R<sup>4</sup> and R<sup>5</sup> together with the N  
10 atom to which they are attached represent a heterocyclic group of from 3 to 8 atoms;

Y independently represents a phenyl group, NR<sup>4</sup>R<sup>5</sup> or het<sup>4</sup>, the phenyl group being optionally substituted with one or more groups independently selected from halogen, CF<sub>3</sub>, OCF<sub>3</sub>, R<sup>4</sup>, OR<sup>4</sup>, CO<sub>2</sub>R<sup>4</sup>, CONR<sup>4</sup>R<sup>5</sup>, CN, SO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, NR<sup>4</sup>SO<sub>2</sub>Me and -NR<sup>4</sup>R<sup>5</sup>;

15

het<sup>1</sup> represents a 4-, 5- or 6- membered saturated, or unsaturated, heterocyclic group containing at least one N (but which may also contain one or more O or S atoms);

het<sup>2</sup> represents a 4-, 5-, 6- or 7- membered saturated, or unsaturated, heterocyclic group  
20 containing at least one N (but which may also contain one or more O or S atoms), optionally substituted with one or more groups independently selected from the list defined below;

het<sup>3</sup> represents a 4-, 5-, 6- or 7- membered saturated, or unsaturated, heterocyclic group  
25 containing at least one O (but which may also contain one or more N or S atoms), optionally substituted with one or more groups independently selected from the list defined below;

het<sup>4</sup> represents a 4-, 5-, 6- or 7- membered saturated or unsaturated heterocyclic group  
30 containing at least one N (but which may also contain one or more O or S atoms), optionally substituted with one or more groups independently selected from the list defined below;

substituents for R<sup>2</sup>, Ring **B**, het<sup>1</sup>, het<sup>2</sup>, het<sup>3</sup> and het<sup>4</sup> are independently selected from the  
35 following list: halogen, CF<sub>3</sub>, OCF<sub>3</sub>, R<sup>3</sup>, -(CH<sub>2</sub>)<sub>e</sub>-SO<sub>2</sub>Me, -(CH<sub>2</sub>)<sub>e</sub>-OR<sup>3</sup>, -(CH<sub>2</sub>)<sub>e</sub>-CO<sub>2</sub>R<sup>3</sup>, -

$(\text{CH}_2)_e\text{-CONR}^4\text{R}^5$ ,  $-(\text{CH}_2)_e\text{-CN}$ ,  $-(\text{CH}_2)_e\text{-SO}_2\text{NR}^4\text{R}^5$ ,  $-(\text{CH}_2)_e\text{-NR}^3\text{SO}_2\text{Me}$ ,  $-(\text{CH}_2)_e\text{-COR}^3$ ,  $-(\text{CH}_2)_e\text{-OCOR}^3$ ,  $-(\text{CH}_2)_e\text{-NHCOR}^3$ ,  $-(\text{CH}_2)_e\text{-NR}^3\text{COR}^6$  and  $-(\text{CH}_2)_e\text{NR}^4\text{R}^5$ ;  
 at each occurrence  $\text{R}^6$  independently represents H,  $\text{C}_1\text{-C}_6$  alkyl optionally substituted by Y,  
 $-(\text{CH}_2)_g\text{-[C}_3\text{-C}_8\text{ cycloalkyl]}$ , phenyl, benzyl, pyridyl or pyrimidyl;

5

a and b independently represent 0 or 1;

c, d, e and g independently represent 0, 1, 2, 3 or 4;

10 f independently represents 1, 2, 3 or 4;

provided that:

(i) a + b cannot equal 0; and

15

(ii) provided that when  $\text{R}^1$  represents  $-(\text{CH}_2)_c\text{-Z-(CH}_2)_d\text{-W}$  and W represents  $\text{NR}^4\text{R}^5$  or any N linked heterocyclic group then d must not be 0 or 1; and

20

(iii) provided that when  $\text{R}^2$  represents a phenyl group substituted by a group of formula  $-(\text{CH}_2)_e\text{OR}^3$ ,  $-(\text{CH}_2)_e\text{-CO}_2\text{R}^3$  or  $-(\text{CH}_2)_e\text{OCOR}^3$ ; or  $\text{het}^1$  and/or  $\text{het}^2$  are substituted by a group of formula  $-(\text{CH}_2)_e\text{OR}^3$ ,  $-(\text{CH}_2)_e\text{-CO}_2\text{R}^3$  or  $-(\text{CH}_2)_e\text{OCOR}^3$ ; or when  $\text{R}^7$  represents  $-\text{OR}^3$  or  $-(\text{CH}_2)_f\text{-O-(CH}_2)_e\text{-R}^3$  and e is 0; or when W represents a phenyl group substituted with  $-\text{OR}^3$  or  $-\text{CO}_2\text{R}^3$ ; and

25

$\text{R}^3$  represents an alkyl group substituted with Y, and Y represents  $\text{NR}^4\text{R}^5$  or an N-linked  $\text{het}^3$ ;  
 then  $\text{R}^3$  must represent  $\text{C}_2\text{-C}_6$  alkyl substituted with Y.

30 2. A compound according to claim 1, wherein  $\text{R}^2$  is a phenyl group optionally substituted with one or more groups selected from halogen or  $-(\text{CH}_2)_e\text{-OR}^3$ .

3. A compound according to claim 1 or claim 2, wherein ring A is selected from piperidindiyl, piperazindiyl, azetidindiyl or pyrrolidindiyl.

35

4. A compound according to claim 3, wherein ring A is piperidindyl.
5. A compound according to any of the preceding claims, wherein Z is O.
6. A compound according to any of the preceding claims, wherein het<sup>1</sup> is selected from
  - 5 optionally substituted pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, triazolyl, tetrazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, piperidinyl, piperazinyl, azetidiny, morpholinyl, 2-oxa-5-aza-bicyclo[2.2.1]heptanyl or pyrrolidinyl.
7. A compound according to any claim 6, wherein het<sup>1</sup> is selected from pyridinyl or
  - 10 pyrimidinyl, optionally by R<sup>3</sup>.
8. A compound according to any of the preceding claims, wherein het<sup>2</sup> is selected from substituted or unsubstituted pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, triazolyl, tetrazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, piperidinyl,
  - 15 piperazinyl, N-methyl piperazinyl, azetidiny, morpholinyl, 2-oxa-5-aza-bicyclo[2.2.1]heptanyl or pyrrolidinyl.
9. A compound according to claim 8, wherein het<sup>2</sup> is selected from imidazolyl, piperidinyl, piperazinyl, N-methyl piperazinyl, azetidiny, morpholinyl, 2-oxa-5-aza-
  - 20 bicyclo[2.2.1]heptanyl or pyrrolidinyl.
10. A compound according to any of the preceding claims, wherein a is 1 and b is 0.
11. A compound according to claim 1, which is selected from
  - 25 (S)-4-[5-Butyl-4-(1-phenyl-ethyl)-4*H*-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
  - 2-[4-(4-Benzyl-5-isobutyl-4*H*-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrimidine;
  - (S)-4-[5-Methyl-4-(1-phenyl-ethyl)-4*H*-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
  - 30 4-[4-Benzyl-5-butyl-4*H*-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
  - 2-[4-(4-Benzyl-5-isopropyl-4*H*-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrimidine;
  - 2-[4-(4-Benzyl-5-cyclopropyl-4*H*-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrimidine;
  - (S)-2-[4-[5-Methyl-4-(1-phenyl-propyl)-4*H*-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrimidine;
  - 35 2-[4-(4-Benzyl-5-propyl-4*H*-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrimidine;

- 2-{4-[4-Benzyl-5-(2-chloro-phenoxy-methyl)-4*H*-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine;
- 2-[4-(4-Benzyl-5-butyl-4*H*-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrimidine;
- (*S*)-2-{4-[5-Methyl-4-(1-phenyl-ethyl)-4*H*-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine;
- 5 2-[4-[4-Benzyl-5-(4-fluoro-phenoxy-methyl)-4*H*-[1,2,4]triazol-3-yl]-piperidin-1-yl]-pyrimidine;
- 2-{4-[5-Methyl-4-(3-methyl-benzyl)-4*H*-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine;
- (*S*)-2-{4-[5-Methyl-4-(1-phenyl-ethyl)-4*H*-[1,2,4]triazol-3-ylmethyl]-piperidin-1-yl}-pyrimidine;
- 10 2-{4-[4-(3-Fluoro-benzyl)-5-methyl-4*H*-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine;
- 4-(4-Benzyl-5-morpholin-4-ylmethyl-4*H*-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
- 4-(4-Benzyl-5-benzyloxymethyl-4*H*-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
- 15 4-(4-Benzyl-5-methyl-4*H*-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
- (*R*)-2-[3-Methyl-5-(1-pyrimidin-2-yl-piperidin-4-yl)-[1,2,4]triazol-4-yl]-2-phenyl-ethanol;
- 2-[4-(4-Benzyl-5-methyl-4*H*-[1,2,4]triazol-3-yl)-piperidin-1-yl]-4-methyl-pyrimidine;
- 2-[4-(4-Benzyl-5-methyl-4*H*-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrimidine;
- 20 4-(4-Benzyl-5-methyl-4*H*-[1,2,4]triazol-3-yl)-1-phenyl-piperidine;
- 2-[4-(4-Benzyl-5-methyl-4*H*-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrazine;
- 4-(4-Benzyl-5-piperidin-1-ylmethyl-4*H*-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
- (*S*)-4-[4-(1-Phenyl-ethyl)-5-piperidin-1-ylmethyl-4*H*-[1,2,4]triazol-3-yl]-3,4,5,6-
- 25 tetrahydro-2*H*-[1,2']bipyridinyl;
- 4-[4-Benzyl-5-(4-methoxy-piperidin-1-ylmethyl)-4*H*-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
- (*S*)-4-[5-(4-Methoxy-piperidin-1-ylmethyl)-4-(1-phenyl-ethyl)-4*H*-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
- 30 4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl-4-yl)-4*H*-[1,2,4]triazol-3-ylmethyl]-piperazine-1-carboxylic acid benzyl ester;
- 4-[4-Benzyl-5-(2-morpholin-4-yl-ethoxymethyl)-4*H*-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl.
- 4-[4-Benzyl-5-((3*R*)-3-methoxy-pyrrolidin-1-ylmethyl)-4*H*-[1,2,4]triazol-3-yl]-3,4,5,6-
- 35 tetrahydro-2*H*-[1,2']bipyridinyl

- 4-[4-Benzyl-5-((3S)-3-methoxy-pyrrolidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 1-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-pyrrolidin-3-ol
- 5 4-(4-Benzyl-5-pyrrolidin-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-[4-Benzyl-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-[4-Benzyl-5-(4-methoxy-piperidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 10 4-[4-(4-Fluoro-benzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-[4-(3-Methoxy-benzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 15 4-[5-Methyl-4-(3-methyl-benzyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-[4-(3-Chloro-benzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-yl]-acetamide
- 20 2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]-ethylamine
- [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-ethyl-amine
- 25 [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-(2-methoxy-ethyl)-amine
- [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-(3-methoxy-propyl)-amine
- 1-{4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-piperazin-1-yl}-ethanone
- 30 4-[4-Benzyl-5-(4-methanesulfonyl-piperazin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl
- N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-methanesulfonamide

- [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-(2-methoxy-ethyl)-methyl-amine
- [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-(3-methoxy-propyl)-methyl-amine
- 5 4-(4-Benzyl-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl)-3'-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-(4-Benzyl-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl)-3'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-(4-Benzyl-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carbonitrile
- 10 4-(4-Benzyl-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carboxylic acid amide
- (S)-4-[4-(1-Phenyl-ethyl)-5-(4-pyridin-2-yl-piperazin-1-ylmethyl)-4H-[1,2,4]triazol-3-ylmethyl]-morpholine trihydrochloride
- 15 (S)-4-[4-(1-Phenyl-ethyl)-5-(4-pyrimidin-2-yl-piperazin-1-ylmethyl)-4H-[1,2,4]triazol-3-ylmethyl]-morpholine trihydrochloride
- 1-[4-Benzyl-5-(1-pyrimidin-2-yl-piperidin-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-piperidin-3-ol
- (R)- 2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester
- 20 (R)-4-[4-Benzyl-5-(tetrahydro-furan-3-yloxymethyl)-4H-[1,2,4]triazol-3-yl] 3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- (S)-4-[4-Benzyl-5-(tetrahydro-furan-3-yloxymethyl)-4H-[1,2,4]triazol-3-yl] 3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 25 {[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-methyl-amino}-acetic acid tert-butyl ester
- 4-[4-Benzyl-5-(tetrahydro-pyran-4-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-[4-Benzyl-5-(tetrahydro-furan-2-yl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 30 4-(4-Benzyl-5-ethoxymethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-[4-Benzyl-5-(2-methoxy-ethoxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]-acetic acid tert-butyl ester

N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]-acetamide

5 4-(4-Benzyl-5-methylsulfanylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

4-(4-Benzyl-5-pyrazol-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

10 4-(4-Benzyl-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

4-(4-Benzyl-5-[1,2,3]triazol-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

4-[4-Benzyl-5-(pyridin-4-yloxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl.

15

12. A compound according to claim 11, which is selected from:

4-[4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

4-(4-Benzyl-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

20 4-(4-Benzyl-5-benzyloxymethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

4-(4-Benzyl-5-piperidin-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

25 (S)-4-[4-(1-Phenyl-ethyl)-5-piperidin-1-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl


4-[4-Benzyl-5-(4-methoxy-piperidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

30 13. The use of a compound according to formula (I) as a medicament.

14. A method of treatment of aggression, Alzheimer's disease, anorexia nervosa, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, cerebrovascular ischemia, cirrhosis, cognitive disorder, Cushing's disease, depression, diabetes mellitus, dysmenorrhoea, edema, 35 emesis, endometriosis, gastrointestinal disease, glaucoma, gynaecological disease, heart



- disease, hypertension, hyponatremia, intrauterine growth retardation, ischemia, ischemic heart disease, lung tumor, micturition disorder, mittelschmerz, motion sickness, neoplasm, nephrotoxicity, non-insulin dependent diabetes, obesity, obsessive/compulsive disorder, ocular hypertension, premature ejaculation, premature labor, pulmonary disease, Raynaud's disease, renal disease, renal failure, male and female sexual dysfunction, sleep disorder, spinal cord injury, thrombosis, urogenital tract infection, urolithiasis, comprising administering a therapeutically effective amount of a compound of formula (I) to a patient suffering from such a disorder.
- 10 15. A method according to claim 14 wherein the disorder is dysmenorrhoea.
- 15 16. The use of a compound of formula (I) in the manufacture of a medicament for the treatment of aggression, Alzheimer's disease, anorexia nervosa, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, cerebrovascular ischemia, cirrhosis, cognitive disorder, Cushing's disease, depression, diabetes mellitus, dysmenorrhoea, edema, emesis, endometriosis, gastrointestinal disease, glaucoma, gynaecological disease, heart disease, hypertension, hyponatremia, intrauterine growth retardation, ischemia, ischemic heart disease, lung tumor, micturition disorder, mittelschmerz, motion sickness, neoplasm, nephrotoxicity, non-insulin dependent diabetes, obesity, obsessive/compulsive disorder, ocular hypertension, premature ejaculation, premature labor, pulmonary disease, Raynaud's disease, renal disease, renal failure, male and female sexual dysfunction, sleep disorder, spinal cord injury, thrombosis, urogenital tract infection, urolithiasis.
- 20 25 17. Use according to claim 16 for the treatment of dysmenorrhoea.
18. A pharmaceutical formulation including a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable excipients, diluent or carrier;
- 30 19. An intermediate of formula (II):



wherein R<sup>1</sup>, rings A and B, and b are as defined in claim 1.

20. Use of a V1a antagonist in combination with an oral contraceptive for the treatment  
5 of dysmenorrhoea.

21. Use according to claim 20 wherein the V1a antagonist comprises a compound  
according to any of claims 1 to 12.